Welcome to our dedicated page for Ra Medical Systems news (Ticker: RMED), a resource for investors and traders seeking the latest updates and insights on Ra Medical Systems stock.
Ra Medical Systems, Inc. (NYSE: RMED) is a pioneering developer of excimer laser technologies for vascular and dermatological treatments, now expanding into cardiac electrophysiology solutions. This news hub provides investors and healthcare professionals with timely updates on regulatory milestones, clinical advancements, and strategic initiatives shaping the company's transition to Catheter Precision, Inc.
Access comprehensive coverage of RMED's innovative medical devices including the VIVO™ imaging system and DABRA catheter technology. Track developments in international expansion efforts and key partnerships driving adoption of minimally invasive therapies. Our curated news collection ensures you stay informed about FDA clearances, European regulatory progress, and evolving treatment applications.
Find updates on:
• New product approvals and clinical trial results
• Strategic partnerships with medical distributors
• Regulatory filings including CE Mark applications
• Hospital adoption metrics for vascular therapies
• Corporate restructuring and leadership changes
Bookmark this page for verified updates on RMED's transition to cardiac-focused innovation. Check regularly for objective reporting on technological breakthroughs impacting both patient care and long-term shareholder value.
Ra Medical Systems (RMED) reported Q4 2020 financial results, achieving net revenue of $1.2 million, a decrease from $1.4 million in Q4 2019. The revenue from the vascular segment was minimal, while dermatology revenue remained steady at $1.2 million. The net loss for Q4 2020 was $10.4 million, compared to a loss of $9.7 million in Q4 2019. For the full year, RMED's revenue was $4.4 million, down from $7.2 million in 2019. The company also reported cash reserves of $23.9 million and a focus on clinical trials and product development.
Ra Medical Systems (NYSE American: RMED), a medical device firm, will participate in two virtual investment conferences: the 33rd Annual Roth Conference from March 15-17, 2021, with virtual investor meetings, and the Maxim 2021 Emerging Growth Virtual Conference from March 17-19, 2021, where CEO Will McGuire will present a company overview. The corporate presentation is accessible on their website. Ra Medical specializes in excimer lasers and catheters for treating vascular and dermatological conditions, with FDA-cleared products like the DABRA and Pharos systems.
Ra Medical Systems (NYSE: RMED) will report its 2020 Q4 and full-year financial results after market close on March 16, 2021. The management team will host a conference call for the investment community at 1:30 PM PT to discuss results and provide company updates. Participants can pre-register for immediate access or join live by calling specified numbers. Ra Medical specializes in excimer laser technology for treating vascular and dermatological diseases, with FDA-cleared products like DABRA and Pharos.
Ra Medical Systems (NYSE American: RMED) will participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. The company will present its overview and engage in virtual meetings with investors. The webcast will be accessible starting March 9, 2021, at 7:00 a.m. Eastern Time until March 10, 2021, at 9:00 p.m. Eastern Time. Ra Medical's products include the DABRA and Pharos excimer laser systems, both FDA-approved for treating vascular and dermatological diseases, and are manufactured in a certified facility in Carlsbad, California.
Ra Medical Systems (RMED) announces the appointment of Susanne L. Meline to its Board of Directors effective January 31, 2021, increasing Board membership to seven. Meline brings over 20 years of experience in finance and corporate governance, co-founding Francis Capital Management, a current shareholder. Her insights, as an observer in Board meetings, are valued by the leadership. Meline aims to enhance shareholder value and patient outcomes. Ra Medical is known for its excimer laser systems, FDA-cleared for treating vascular and dermatological diseases.
Ra Medical Systems (NYSE American: RMED) announces advancements in its next generation DABRA catheter, aimed at treating vascular diseases. The company has completed a quality improvement plan and initial testing suggests a shelf life of six months or more. The issues impacting shelf life have been identified and mitigated through changes in materials and processes. Expected completion of further engineering work is by mid-2021, followed by an FDA submission. CEO Will McGuire expresses optimism about the progress and dedication to quality enhancements.
Ra Medical Systems, Inc. (NYSE American: RMED) announces its participation in the H.C. Wainwright Virtual BioConnect Conference. Management will present on the company's excimer laser systems, aimed at treating vascular and dermatological diseases.
The presentation is available for registration on the conference website from January 11, 2021, 6:00 a.m. ET to January 14, 2021, 9:00 p.m. ET. Ra Medical's DABRA and Pharos systems are FDA-cleared and manufactured in California, focusing on chronic total occlusions and various skin conditions.
Ra Medical Systems (NYSE American: RMED) announced a settlement with the U.S. Department of Justice regarding civil False Claims Act claims related to its DABRA laser system. The company will pay $2.5 million immediately and may owe up to $3.25 million more if revenue exceeds $10 million over the next four fiscal years. Additionally, a change-in-control transaction could incur up to $28 million in settlement payments. A five-year Corporate Integrity Agreement has also been established. The company emphasizes its commitment to compliance and advancing treatments for vascular and dermatological diseases.
Ra Medical Systems, Inc. (NYSE: RMED) has announced its common stock will be listed on the NYSE American starting December 22, 2020. This transfer from the New York Stock Exchange is seen as a better fit for the company's capital structure. CEO Will McGuire emphasized the importance of maintaining a long-term relationship with the NYSE. Ra Medical focuses on excimer laser systems for treating vascular and dermatological conditions, with FDA-cleared products like the DABRA and Pharos excimer laser systems.
Ra Medical Systems (NYSE: RMED) has launched a webcast titled The Inimitable Role of Excimer Lasers During the COVID-19 Pandemic. The event features Dr. Theodore J. Daly, discussing the efficacy of excimer lasers in treating psoriasis amid the pandemic. He highlights the safety of using excimer lasers over immunosuppressive agents, citing significant success in patient outcomes. Ra Medical manufactures excimer lasers for dermatological conditions and is committed to informing healthcare professionals about innovative treatment options during challenging times.
